Cardiff Oncology (Cardiff Oncology) Additional Paid-In Capital : $409.34 Mil(As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Additional Paid-In Capital?

Cardiff Oncology's quarterly additional paid-in capital increased from Jun. 2023 ($407.48 Mil) to Sep. 2023 ($408.43 Mil) and increased from Sep. 2023 ($408.43 Mil) to Dec. 2023 ($409.34 Mil).

Cardiff Oncology's annual additional paid-in capital increased from Dec. 2021 ($400.50 Mil) to Dec. 2022 ($404.83 Mil) and increased from Dec. 2022 ($404.83 Mil) to Dec. 2023 ($409.34 Mil).

Cardiff Oncology Additional Paid-In Capital Historical Data

The historical data trend for Cardiff Oncology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Additional Paid-In Capital Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

217.17

361.82

400.50

404.83

409.34

Cardiff Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															404.83	405.90	407.48	408.43	409.34

Cardiff Oncology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cardiff Oncology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (Cardiff Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116